1. Introduction {#sec1-cancers-12-02254}
===============

Soft tissue sarcoma (STS) comprises approximately 50 subtypes of tumors characterized by their mesenchymal origin and heterogeneous phenotype \[[@B1-cancers-12-02254]\]. Although STS is a rare tumor entity, with an incidence rate of only 3.6 per 100,000 \[[@B2-cancers-12-02254]\], the low five-year survival rate of 50% is a major issue \[[@B3-cancers-12-02254]\]. Therefore, there is still an urgent need for reliable, specific, and easily measurable prognostic markers for risk stratification and subsequent therapy management.

MicroRNAs are 18--25 nucleotide long, noncoding RNAs that post-transcriptionally regulate gene expression by repressing the translation of their respective target genes through RNA-induced silencing complex (RISC)-mediated binding to the 3′-UTR and subsequent inhibition of proper ribosomal assembly \[[@B4-cancers-12-02254]\]. Frequently, microRNA expression patterns are specific for physiologic tissues, but also systemic diseases or malignancies. In this context, sarcomas have been subject to a characterization of the individual microRNA patterns putatively associated with their heterogeneous appearance and tumor-biological behavior (reviewed in \[[@B5-cancers-12-02254]\]).

Furthermore, there is a multitude of studies showing a considerable impact of the dysregulation of certain microRNAs in all major malignancies on the prognosis of patients. Previously, we were able to demonstrate an association between increased miR-155, miR-210, or miR-203 expression and a significantly worsened prognosis in pancreatic adenocarcinoma \[[@B6-cancers-12-02254]\]. An intermediate miR-210 level was also associated with worsened survival in STS patients \[[@B7-cancers-12-02254]\].

MiR-155-5p (henceforth designated miR-155) and its complementary strand miR-155-3p are processed from the B-cell integration cluster (BIC) gene located on chromosome 21, which is alternatively designated the MIR155 host gene (MIR-155HG). Although miR-155 plays a role in hematopoiesis, inflammation, and immune responses, it may act as an oncogenic miRNA. It is not only upregulated in different leukemias and lymphomas, but also in solid tumors such as cancer of the breast, colon, lung, pancreas, and thyroid (reviewed in \[[@B8-cancers-12-02254]\]). Furthermore, miR-155 was reported to be overexpressed in liposarcoma (LS)-derived cell lines or liposarcoma biopsies in comparison to normal fat tissue \[[@B9-cancers-12-02254],[@B10-cancers-12-02254]\] and contribute to LS progression by targeting the central Wnt pathway component casein kinase 1α (CK1α) \[[@B9-cancers-12-02254]\]. Interestingly, the Kaposi sarcoma-associated herpesvirus genome encodes an ortholog of miR-155 \[[@B11-cancers-12-02254]\], and overexpression of this viral-encoded microRNA is associated with the suppression of cell growth control \[[@B12-cancers-12-02254]\]. MiR-155 is also overexpressed in osteosarcoma samples in comparison to corresponding normal tissue and targets the Wnt pathway repressor HMG-box transcription factor 1 (HBP1), thereby driving osteosarcoma cell proliferation by enhancing Wnt pathway action \[[@B13-cancers-12-02254]\]. Further important cellular pathways regulated by miR-155 in osteosarcoma include the PTEN/AKT/mTOR pathway \[[@B14-cancers-12-02254]\] and the NFκB pathway \[[@B15-cancers-12-02254]\].

The miR-203a gene is located on chromosome 14q32.33 \[[@B16-cancers-12-02254]\]. MiR-203a-3p (henceforth designated as miR-203) is expressed aberrantly in different cancers, such as gastric, pancreatic, colon and esophageal cancer, compared to normal tissue (reviewed in \[[@B17-cancers-12-02254],[@B18-cancers-12-02254]\]), which suggests its expression to serve as a diagnostic marker. MiR-203 was identified to be downregulated both in rhabdomyosarcoma (RMS) cell lines and in rhabdomyosarcoma patient samples due to promoter hypermethylation. Re-induction of miR-203 expression by demethylating agents downregulates p63 and leukemia inhibiting factor receptor (LIFR) \[[@B19-cancers-12-02254]\]. Furthermore, miR-203 is significantly downregulated in osteosarcoma samples and cell lines compared to controls, while its target gene RAS-related protein Rab22A (RAB22A) is overexpressed. Conversely, the overexpression of miR-203 blocks osteosarcoma growth and migration \[[@B20-cancers-12-02254]\].

In this study, we aimed to analyze the impact of miR-155 and miR-203 on the diagnostics as well as the correlation with clinical characteristics and with the prognosis of STS patients.

2. Results {#sec2-cancers-12-02254}
==========

2.1. miR-155 and miR-203 Expression in STS Specimens {#sec2dot1-cancers-12-02254}
----------------------------------------------------

MiR-155 and miR-203 were detectable in all analyzed STS specimens, with median expression values of 16.7 and 1.9, respectively. The distribution of miR-155 expression values ranged from 0.3--189.5, while miR-203 expression values ranged from 0.003 to 14358.7.

By using recursive partitioning methods, we established the influence and optimized cut-offs of each microRNA when analyzing the combinational effect on STS patient survival. With an expression of miR-203 ≥ 0.56 and miR-155 ≥ 42.92, there was a 68% correct classification rate of tumor-related death in the STS patients (see [Figure 1](#cancers-12-02254-f001){ref-type="fig"}).

Optimized cut-off values were also defined by assessing the value with the highest Youden index in receiver operating characteristics (ROC) analyses, testing the sensitivity and specificity of each microRNA in the tumor-related death of the patients (see [Figure 2](#cancers-12-02254-f002){ref-type="fig"}).

The optimal cut-off was 18.0 for miR-155 and 0.9 for miR-203. When assessing low and high expression of the microRNAs with respect to age, gender, tumor stage, resection type, tumor localization, and histological subtypes of the respective tumor, we detected a significant association between increased miR-155 expression and increased tumor stage (*p* = 0.01, Kruskal--Wallis test, see [Figure 3](#cancers-12-02254-f003){ref-type="fig"}).

Regarding the histological subtype, especially liposarcoma and neuronal sarcoma exhibited a lower miR-155 expression in comparison to the other sarcoma entities (see [Supplementary Figure S1](#app1-cancers-12-02254){ref-type="app"}). These differences were significant (*p* = 0.001, Kruskal--Wallis test). However, this was based on relatively low case numbers (*n* = 7--21 per category).

2.2. Bivariate Correlation Analyses {#sec2dot2-cancers-12-02254}
-----------------------------------

We analyzed the molecular biological factors associated with miR-155 and miR-203 expression in soft tissue sarcoma. When considering all significant correlations with r~s~ \> 0.25 or r~s~ \< −0.25, we retrieved eight and five factors associated with miR-155 and miR-203, respectively (see [Table 1](#cancers-12-02254-t001){ref-type="table"}).

Both miR-155 and miR-203 expression levels were significantly correlated with miR-210 expression. Moreover, miR-155 expression was significantly correlated with the expression of proteins of the urokinase-type plasminogen activator (uPA) system (r~s~ = 0.347--0.604, Spearman-Rho) and the tumor tissue level of osteopontin (OPN) in the tumors of STS patients (r~s~ = 0.361). Additionally, miR-155 expression was significantly associated with ephrin-A3 (EFNA3) mRNA expression (r~s~ = −0.378) and LGR5 mRNA expression (r~s~ = −0.389). MiR-203 was significantly inversely associated with OPN mRNA expression (splice variants a-c: r~s~ = −0.26--−0.324) and pAKT tumor tissue level (r~s~ = −0.434).

2.3. Survival Analyses {#sec2dot3-cancers-12-02254}
----------------------

Finally, we tested the association of miR-155 and miR-203 expression with the prognosis of STS patients. In Kaplan--Meier survival analyses, elevated miR-155 expression (≥18.0) was significantly associated with worsened tumor-related survival (median survival time 25 months in comparison to 118 months; see [Figure 4](#cancers-12-02254-f004){ref-type="fig"}a). On the other hand, lower miR-203 expression (\<0.9) was significantly associated with worsened tumor-related survival in the STS patients (median survival time 18 months vs. 86 months, see [Figure 4](#cancers-12-02254-f004){ref-type="fig"}b).

Furthermore, when combining the expression of both microRNAs, the unfavorable combination miR-155 high + miR-203 low was significantly associated with a worsened survival of the patients in comparison to the miR-155 low + miR-203 high combination in tumor tissues (*p* \< 0.001, log-rank-test, see [Figure 4](#cancers-12-02254-f004){ref-type="fig"}c).

In the univariate Cox regression analyses, increased miR-155 expression (*p* = 0.03; RR = 1.96) and decreased miR-203 expression (*p* = 0.002; RR = 2.59) were also associated with a higher risk of tumor-related death (see [Table 2](#cancers-12-02254-t002){ref-type="table"}). When combining both microRNAs, the less favorable combination miR-155 high + miR-203 low exhibited a significant 4.76-fold increased risk of tumor-related death (*p* = 0.001). However, although the estimated risk ratios remained numerically equivalent in multivariate Cox regression analyses adjusted for tumor stage, tumor localization, resection type, and STS sub-entity, the association between miR-155 or the combination of miR-155 and miR-203 was no longer an independent predictor of STS patient survival, probably because of the interdependence of increased miR-155 expression and a higher tumor stage. Furthermore, the relapse-free survival of the patients was not associated with miR-155 or miR-203 expression in uni- or multivariate Cox regression analyses (see [Table 2](#cancers-12-02254-t002){ref-type="table"}).

.

Furthermore, when analyzing the effect of miR-155 or miR-203 on the patients survival in distinct histological subtypes, it became evident that in myogenic sarcomas (rhabdo- and leiomyosarcoma) a lowered miR-155 expression as well as a lowered miR-203 expression was significantly associated to a worsened survival of the STS patients (See [Table S1](#app1-cancers-12-02254){ref-type="app"}).

3. Discussion {#sec3-cancers-12-02254}
=============

We measured miR-155 and miR-203 expression in 79 soft tissue sarcoma (STS) specimens. Both microRNAs were detectable in all samples to a different extent, with higher expression of miR-155 than miR-203. This is consistent with the general theory of miR-155 being an oncomiR (cancer-associated microRNA) defined by its general upregulation in lymphomas, leukemias, and solid tumors \[[@B8-cancers-12-02254],[@B27-cancers-12-02254],[@B28-cancers-12-02254]\], and miR-203 being a tumor suppressor miR due to its general downregulation in many tumor entities \[[@B20-cancers-12-02254],[@B29-cancers-12-02254],[@B30-cancers-12-02254]\]. Interestingly, several groups report miR-155 to be overexpressed, especially in liposarcoma in comparison to normal fat tissue \[[@B9-cancers-12-02254],[@B10-cancers-12-02254]\]. We did not observe any association between the STS sub-entities present in our cohort and altered miR-155 expression; however, we could not monitor normal tissue corresponding to our tumor specimens. On the other hand, increased miR-155 expression was significantly associated with elevated tumor stage in our STS cohort. Higher expression of miR-155 in connection with advanced tumor stages was also observed in breast cancer \[[@B31-cancers-12-02254]\], laryngeal squamous cell carcinoma \[[@B32-cancers-12-02254]\], or chordoma \[[@B33-cancers-12-02254]\]. In contrast, miR-155 expression in pediatric Wilms tumors was lower in advanced tumor stages and increased due to chemotherapy \[[@B34-cancers-12-02254]\].

MiR-155 and miR-203 expression was correlated with several--mainly hypoxia-associated--molecular factors in our STS cohort. MiR-155 was significantly positively correlated with the hypoxia-dependent microRNA miR-210 and inversely correlated with the mRNA expression of the known miR-210 target gene ephrin-A3 (EFNA3) \[[@B6-cancers-12-02254],[@B35-cancers-12-02254]\]. There is a negative feed-back-loop between miR-155 and von-Hippel-Lindau factor (VHL) \[[@B36-cancers-12-02254]\]. On one hand, the VHL protein suppresses miR-155 and miR-210 expression. On the other hand, Kong and colleagues demonstrated the pivotal role of miR-155 in tumor angiogenesis of breast cancer tissue through targeting VHL and subsequent HIF-1α stabilization \[[@B36-cancers-12-02254]\]. They suggest that miR-155 regulates the VHL/HIF pathway to induce tumor angiogenesis and metastasis in triple-negative breast cancer. Furthermore, miR-210 is upregulated by HIF-1α and therefore it is possible that miR-155 indirectly increases miR-210 by stabilizing hypoxia inducible factor 1 subunit alpha (HIF1α). In this way, increasing miR-210 levels can reduce mRNA levels of its target gene EFNA3.

Additionally, we found a correlation between miR-155 expression and p53 mutation status. This is in accordance with previous findings demonstrating that miR-155 can be downregulated by wild-type p53, p63 and breast cancer type 1 susceptibility protein (BRCA1). However, an upregulation of miR-155 through mutant p53 or mutant BRCA1 has been reported (reviewed in \[[@B8-cancers-12-02254],[@B37-cancers-12-02254]\]).

Moreover, we detected a significant association between increased miR-155 expression and several components of the uPA system, namely, uPA, uPAR, and PAI-1. The expression of miR-155 is also positively correlated with the expression of serpine1/PAI-1 in breast cancer \[[@B37-cancers-12-02254]\]. Wild-type p53 represses uPA transcription by repressing the uPA promoter and enhancer \[[@B38-cancers-12-02254]\]. However, oncogenic p53 mutants exhibit a significant loss or total ablation of this repressing activity \[[@B38-cancers-12-02254]\]. Altogether, the correlation of miR-155 expression with the whole uPA system warrants further investigation.

In addition, the miR-155 level is negatively correlated with the mRNA expression level of the stem cell marker leucine rich repeat containing G protein-coupled receptor 5 (LGR5) \[[@B24-cancers-12-02254]\]. However, LGR5 does not appear to be a direct target of miR-155 (<http://mirtar.mbc.nctu.edu.tw/human/>). Interestingly, LGR5-induced p53 degradation was described for hepatocellular carcinoma cells, which was also associated with therapeutic resistance against doxorubicin \[[@B39-cancers-12-02254]\]. It appears that there is a LGR5/p53/miR-155 axis, but this needs further investigation.

MiR-203 is negatively associated with the expression of several osteopontin splice variants. Interestingly, neither the existing literature nor available databases (TargetScan.org) hint at the direct targeting of OPN by miR-203. However, a reduction in OPN mRNA/protein under hypoxia has been reported in normal human cells \[[@B40-cancers-12-02254]\]. Therefore, it remains to be elucidated whether there is a direct or indirect regulation of this gene by miR-203. Furthermore, a negative correlation between miR-203 expression and the protein level of phosphorylated AKT (pAKT) was observed in our study. This is in agreement with the findings of Yang and coworkers \[[@B41-cancers-12-02254]\]. They identified phosphatidylinositol 4,5-bisphosphate 3-kinase (PIK3CA) as a direct target gene of miR-203. Inhibition of miR-203 resulted in increased levels of pAKT and pPIK3CA. Therefore, they suggest that miR-203 targets the PI3K/Akt signaling pathway \[[@B41-cancers-12-02254]\].

In our cohort, increased miR-155 expression exhibited a significant negative impact on STS patient survival, which was demonstrated for different STS entities for the first time. In this way, our results support the findings of Kapodistrias and colleagues, who showed that increased miR-155 expression is an independent indicator of unfavorable prognosis in liposarcoma \[[@B42-cancers-12-02254]\]. In non-small-cell lung cell carcinoma, the effect of miR-155 expression on patient survival was dependent on the histological subtype, with negative effects of increased miR-155 expression in adenocarcinoma and decreased miR-155 expression in squamous cell carcinoma \[[@B43-cancers-12-02254]\]. However, in general, increased miR-155 expression is associated with worsened survival in tumor patients, as seen in pancreatic ductal adenocarcinoma \[[@B6-cancers-12-02254]\], colorectal carcinoma \[[@B44-cancers-12-02254]\], hepatocellular carcinoma \[[@B45-cancers-12-02254]\], breast cancer \[[@B46-cancers-12-02254]\], glioma \[[@B47-cancers-12-02254]\], osteosarcoma \[[@B13-cancers-12-02254]\], or leukemia \[[@B48-cancers-12-02254]\].

On the other hand, we identified, for the first time in STS, a significant association between a lower miR-203 expression and a worsened STS patient outcome. The role of miR-203 in tumor patient survival is multifaceted, with increased miR-203 being a negative predictor of patient survival in pancreatic adenocarcinoma \[[@B6-cancers-12-02254],[@B49-cancers-12-02254]\], epithelial ovarian cancer \[[@B50-cancers-12-02254]\], breast cancer \[[@B51-cancers-12-02254]\], colon/colorectal cancer \[[@B52-cancers-12-02254],[@B53-cancers-12-02254]\], and ependymoma \[[@B54-cancers-12-02254]\], but being a positive predictor for patient survival in glioma \[[@B55-cancers-12-02254]\], hepatocellular carcinoma \[[@B56-cancers-12-02254]\], epithelial ovarian cancer \[[@B57-cancers-12-02254]\], and esophageal cancer \[[@B17-cancers-12-02254]\]. MiR-203 has been characterized to act as a tumor suppressor microRNA in laryngeal carcinoma by targeting survivin \[[@B58-cancers-12-02254]\] and in lung cancer by targeting v-src avian sarcoma viral oncogene (SRC) and protein kinase C alpha (PKCα/PRKCA) \[[@B57-cancers-12-02254],[@B59-cancers-12-02254]\]. Furthermore, a tumor suppressive role of miR-203 was shown in prostate cancer \[[@B60-cancers-12-02254]\]. MiR-203 levels are downregulated in clinical samples of primary prostate cancer and further reduced in metastatic prostate cancer \[[@B60-cancers-12-02254]\]. Transfection with miR-203 precursors resulted in a reduction of phosphorylated EGFR and phosphorylated ERK1/2 in DU145 derivative PCa cells. Siu et al suggested that the loss of miR-203 is a molecular link in the progression of prostate cancer metastasis and tyrosine kinase inhibitor (TKI) resistance characterized by high EGFR ligand output and antiapoptotic protein activation \[[@B60-cancers-12-02254]\]. Interestingly, hypoxia can upregulate phosphorylated ERK1/2 in normal human cells \[[@B40-cancers-12-02254]\], and a reduction in miR-203 level is associated with increased phosphorylated ERK1/2 as well \[[@B60-cancers-12-02254]\]. Therefore, both hypoxia and a reduction in miR-203 level may trigger activation of MAPK (ERK1/2)/AKT signaling, which also plays a role in different sarcomas \[[@B61-cancers-12-02254]\].

Altogether, increased miR-155 is associated with more aggressive behavior and poor prognosis in many different cancers, but for miR-203, a controversial picture can be drawn depending on the tumor entity. In this way, miR-155 appears to be a potential target for miRNA-based therapy, as suggested seven years ago \[[@B8-cancers-12-02254]\]. However, the physiological role of miR-155 in myelopoiesis and erythropoiesis should also be considered \[[@B8-cancers-12-02254]\]. Since that time, miRNA therapies have undergone evaluation in several recently undertaken clinical trials where results are eagerly awaited \[[@B62-cancers-12-02254]\]. MiR-155 inhibition by MRG106/cobomarsen was recently tested in a clinical phase 1 study in different leukemia and lymphoma patients (NCT02580552) and in two clinical phase 2 studies in cutaneous T-cell lymphoma/mycosis fungoides patients (NCT03837457, NCT03713320). Our results suggest that inhibition of miR-155 could also have potential as a future treatment option for STS patients.

4. Materials and Methods {#sec4-cancers-12-02254}
========================

4.1. Patients and Specimens {#sec4dot1-cancers-12-02254}
---------------------------

The tumor specimens analyzed in this study originated from 79 adult patients from a previously described STS cohort \[[@B63-cancers-12-02254]\]. The study was approved by the ethics committee of Martin Luther University Halle-Wittenberg (date of approval: 24 January 2007). All patients gave written informed consent. The demographic and clinicopathological details of the patients are summarized in [Table 3](#cancers-12-02254-t003){ref-type="table"}.

4.2. RNA Isolation and cDNA Synthesis {#sec4dot2-cancers-12-02254}
-------------------------------------

Total RNA was isolated by phenol/chloroform extraction using TRIzol reagent (Invitrogen, Karlsruhe, Germany) from 10--30 tumor slides of 10 μm thickness. Briefly, tumor tissue was suspended in TRIzol reagent and vortexed vigorously, and then chloroform (Roth, Karlsruhe, Germany) was added and mixed. The suspension was centrifuged for 10 min at 6000× *g*, and the aqueous phase was mixed with isopropanol (Roth). After precipitation overnight, the RNA pellet was washed twice in ice-cold ethanol (96% and 70%, respectively; Merck, Darmstadt, Germany) and eluted in 20 μL DEPC-treated water (Invitrogen).

Ten nanograms of total RNA was introduced to cDNA synthesis of miR-155, miR-203 and U18 snoRNA (reference gene) with the stem-loop primer system (Applied Biosystems, Darmstadt, Germany). Reverse transcription reactions were carried out with the SuperScript II Reverse transcription kit (Invitrogen, Karlsruhe, Germany) according to the manufacturers' protocols. The qPCR measurements were performed in duplicate with the HotStart Taq Polymerase Kit (Qiagen, Hilden, Germany) on the Rotorgene 3000 real-time PCR system (LTF, Wasserburg, Germany). The resulting mean C~T~ values were analyzed in comparison to U18 snoRNA expression as a reference gene. Further, 2^−ΔCT^ values were designated according to Livak and Schmittgen \[[@B64-cancers-12-02254]\].

4.3. Statistical Analysis {#sec4dot3-cancers-12-02254}
-------------------------

Bivariate linear regression analysis (Spearman's rank test) was applied to test the correlation between miR-155 or miR-203 expression and molecular biological tumor markers. Pearson's Chi^2^ test and nonparametric tests (Kruskal-Wallis test) were applied to detect interdependences between microRNA expression and demographic or clinicopathological parameters. Survival analyses (Kaplan--Meier analyses, uni- and multivariate Cox regression analyses) were performed to test associations between microRNA expression and STS patient survival. All these tests were performed with SPSS 25.0 (IBM, Ehingen, Germany). *p* values ≤ 0.05 were considered significant. ROC analyses and recursive partitioning were applied to test the individual contributions of miR-155 and miR-203 in combined risk stratification. These tests were performed with the R statistical framework (v. 3.2.1; R foundation for statistical computing, Vienna, Austria) and the additional function libraries pROC and rpart.

5. Conclusions {#sec5-cancers-12-02254}
==============

We analyzed the association of miR-155 and miR-203 expression with the prognosis of soft tissue sarcoma patients. Both microRNAs were detectable in all tumor specimens to different extents and exhibited correlations with several hypoxia-associated molecular markers, such as miR-210 and, in the case of miR-155, components of the urokinase-like plasminogen activator (uPA) system and ephrin-A3 (EFNA3). Furthermore, miR-155 expression was higher in advanced tumor stages. The expression of miR-155 and miR-203 as well as the combination of both microRNAs was significantly associated with a worsened disease-specific survival in soft tissue sarcoma patients. In summary, miR-155 and miR-203 are interesting candidates for risk stratification in soft tissue sarcoma patients, and miR-155 may be an option for therapy management in the future.
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![Classification tree establishing the influence of each microRNA in a combinational approach towards risk stratification.](cancers-12-02254-g001){#cancers-12-02254-f001}

![ROC analyses for miR-155 (green), miR-203 (blue) and a combination of miR-155 + miR-203 (model in red) and their prognostic application. Both microRNAs exhibited fair area under the curve values (AUCs; miR-155: AUC 0.62 (0.49--0.74), *p* = 0.067; miR-203: AUC 0.67 (0.55--0.79), *p* = 0.011). MiR-155 or miR-203 expression with the highest Youden index according to single ROC analyses was chosen as the cut-off for subsequent survival analyses. A fitted linear regression model that combined miR-155 and miR-203 also exhibited only a fair AUC of 0.68 (0.56--0.80), *p* = 0.006.](cancers-12-02254-g002){#cancers-12-02254-f002}

![The distribution of miR-155 expression in relation to tumor stage. MiR-155 expression was significantly associated with tumor stage (*p* = 0.01, Kruskal-Wallis test).](cancers-12-02254-g003){#cancers-12-02254-f003}

![Kaplan-Meier survival analyses of the prognostic impact of miR-155 (**a**) and miR-203 (**b**) expression or a combination of both microRNAs (**c**) on soft tissue sarcoma patient survival. Below the figures, the number of patients at risk at specific time points is given.](cancers-12-02254-g004){#cancers-12-02254-f004}

cancers-12-02254-t001_Table 1

###### 

Bivariate correlation analyses (Spearman-Rho) with miR-155 or miR-203 and different molecular-pathological factors in soft tissue sarcoma.

  Parameters                        r~s~      *p*     *n*                           Reference
  ----------------- --------------- --------- ------- ----------------------------- -----------------------------
  miR-155           p53 mutations   0.260     0.040   63                            \[[@B21-cancers-12-02254]\]
  OPN protein       0.361           0.002     72      \[[@B22-cancers-12-02254]\]   
  uPA protein       0.604           \<0.001   79      \[[@B23-cancers-12-02254]\]   
  uPAR protein      0.440           \<0.001   79      \[[@B23-cancers-12-02254]\]   
  PAI-1 protein     0.347           0.002     79      \[[@B23-cancers-12-02254]\]   
  EFNA3 mRNA        −0.378          0.001     75      *n.p.*                        
  LGR5 mRNA         −0.389          0.001     69      \[[@B24-cancers-12-02254]\]   
  miR-210           0.349           0.002     78      \[[@B7-cancers-12-02254]\]    
  miR-203           miR-210         0.265     0.019   78                            \[[@B7-cancers-12-02254]\]
  OPN-a mRNA        −0.267          0.021     74      \[[@B25-cancers-12-02254]\]   
  OPN-b mRNA        −0.324          0.005     74      \[[@B25-cancers-12-02254]\]   
  OPN-c mRNA        −0.260          0.025     74      \[[@B25-cancers-12-02254]\]   
  pAKT473 protein   −0.434          \<0.001   73      \[[@B26-cancers-12-02254]\]   

Abbreviations: r~s~---correlation factor according to Spearman-Rho; *n.p.*---not published own data.

cancers-12-02254-t002_Table 2

###### 

Univariate and multivariate Cox regression survival analyses of the impact of miR-155 and miR-203 on soft tissue sarcoma patient survival. Multivariate Cox regression analyses adjusted for tumor stage, resection type, tumor localization and tumor sub-entity. RR = relative risk with 95% confidence interval in brackets.

  Parameters                   Univariate Cox Regression Analysis   Multivariate Cox Regression Analysis                                                              
  ---------------------------- ------------------------------------ -------------------------------------- ------------------------ ---- ------- -------------------- -----------------------------
  miR-155 low                  45                                                                          Reference                45           Reference            **Tumor-specific survival**
  miR-155 high                 34                                   **0.031**                              **1.96 (1.06--3.61)**    34   0.766   1.13 (0.52--2.46)    
  miR-203 low                  29                                   **0.002**                              **2.59 (1.41--4.76)**    29   0.077   1.99 (0.93--4.25)    
  miR-203 high                 50                                                                          Reference                50           Reference            
  miR-155 low + miR-203 high   29                                                                          Reference                29           Reference            
  miR-155 high + miR-203 low   13                                   **0.001**                              **4.76 (1.89--12.05)**   13   0.21    4.05 (0.46--35.7)    
  miR-155 low                  45                                                                          Reference                45           Reference            **Relapse-free survival**
  miR-155 high                 34                                   0.985                                  1.01 (0.5--2.01)         34   0.512   1.32 (0.34--1.73)    
  miR-203 low                  29                                   0.189                                  1.61 (0.79--3.26)        29   0.405   1.60 (0.21--1.90)    
  miR-203 high                 50                                                                          Reference                50           Reference            
  miR-155 low + miR-203 high   29                                   0.455                                  1.5 (0.23--1.93)         29           Reference            
  miR-155 high + miR-203 low   13                                                                          Reference                13   0.247   3.04 (0.46--19.99)   

Significant values are in bold face.

cancers-12-02254-t003_Table 3

###### 

MiR-155 and miR-203 expression in relation to clinical and histopathological characteristics in soft tissue sarcoma patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameters                             miR-155 Low (\<18.0)   miR-155 High\   Chi^2^ Test (*p*-Value)   miR-203 Low (\<0.9)   miR-203 High (≥0.9)   Chi^2^ Test (*p*-Value)
                                                                (≥18.0)                                                                               
  ----------------------- -------------- ---------------------- --------------- ------------------------- --------------------- --------------------- -------------------------
  age                     \<60 years     23                     20              n.s.                      15                    28                    n.s.

  \>60 years              22             14                     14              22                                                                    

  gender                  female         24                     12              n.s.                      16                    20                    n.s.

  male                    21             22                     13              30                                                                    

  patients status         alive          25                     11              0.04                      7                     29                    0.004

  deceased                20             23                     22              21                                                                    

  tumor stage ^a^         I              12                     1               0.011                     3                     10                    n.s.

  II                      19             12                     10              21                                                                    

  III                     11             15                     11              15                                                                    

  IV                      3              6                      5               4                                                                     

  resection               radical (R0)   32                     21              n.s.                      17                    36                    n.s.

  not radical (R1)        13             13                     12              14                                                                    

  tumor localization      extremities    29                     23              n.s.                      18                    34                    n.s.

  trunk wall              3              2                      2               3                                                                     

  head/neck               2              0                      1               1                                                                     

  abdomen/peritoneum      9              9                      6               12                                                                    

  multiple locations      2              0                      2               0                                                                     

  histological subtypes   LS             12                     9               0.011                     10                    11                    n.s.

  FS + NOS                12             8                      4               16                                                                    

  NS                      4              3                      3               4                                                                     

  RMS + LMS               11             10                     8               13                                                                    

  other                   6              4                      4               6                                                                     

  tumor size              T1             6                      5               n.s.                      3                     8                     n.s.

  T2                      39             29                     26              42                                                                    

  number of relapses      0              28                     20              n.s.                      15                    33                    n.s.

  1                       8              5                      6               7                                                                     

  \>2                     9              9                      8               10                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Union for International Cancer Control Guidelines; Abbreviations: LS---liposarcoma; FS---fibrosarcoma; RMS---rhabdomyosarcoma; LMS---leiomyosarcoma; NS---neuronal sarcoma; Syn---synovial sarcoma; NOS---not otherwise specified; T1---≤5 cm in diameter; T2---\>5 cm in diameter; n.s.---not significant.

[^1]: Both authors contributed equally.
